Agios Presents Updated Data from Phase 1 Dose-Escalation Study of AG-881 in Patients with IDH Mutant Positive Advanced Glioma
Agios and CStone Pharmaceuticals Announce Exclusive Collaboration and License Agreement to Develop and Commercialize Ivosidenib in Greater China
Nuvau Expands Its Exploration Program Targeting Key Base Metal and Never-Before-Drilled Gold Targets in the Matagami District
Spartan Metals Corp Retains Strategic Government Relations Firm to Advance Non-Dilutive Funding Opportunities
